Cite
HARVARD Citation
Curtin, F. et al. (2020). A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes. Diabetes, obesity & metabolism. 22 (7), pp. 1111-1121. [Online].